BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang XH, Qin-Ma, Wu HP, Khamis MY, Li YH, Ma LY, Liu HM. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity. J Med Chem 2021;64:1362-91. [PMID: 33523672 DOI: 10.1021/acs.jmedchem.0c01782] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 T Tavares M, Shen S. Recent innovative advances in the discovery of selective HDAC6 inhibitors. Future Med Chem 2021;13:1017-9. [PMID: 33906379 DOI: 10.4155/fmc-2021-0040] [Reference Citation Analysis]
2 Sabnis RW. 5-Fluoronicotinamide Derivatives as HDAC6 Inhibitors for Treating Heart Diseases. ACS Med Chem Lett 2021;12:953-4. [PMID: 34141079 DOI: 10.1021/acsmedchemlett.1c00282] [Reference Citation Analysis]
3 Xu Y, Tang H, Xu Y, Guo J, Zhao X, Meng Q, Xiao J. Design, Synthesis, Bioactivity Evaluation, Crystal Structures, and In Silico Studies of New α-Amino Amide Derivatives as Potential Histone Deacetylase 6 Inhibitors. Molecules 2022;27:3335. [DOI: 10.3390/molecules27103335] [Reference Citation Analysis]
4 Sabnis RW. Novel Histone Deacetylase 6 Inhibitors for Treating Alzheimer's Disease and Cancer. ACS Med Chem Lett 2021;12:1202-3. [PMID: 34413942 DOI: 10.1021/acsmedchemlett.1c00339] [Reference Citation Analysis]
5 Sandrone G, Cukier CD, Zrubek K, Marchini M, Vergani B, Caprini G, Fossati G, Steinkühler C, Stevenazzi A. Role of Fluorination in the Histone Deacetylase 6 (HDAC6) Selectivity of Benzohydroxamate-Based Inhibitors. ACS Med Chem Lett 2021;12:1810-7. [PMID: 34795871 DOI: 10.1021/acsmedchemlett.1c00425] [Reference Citation Analysis]
6 Xu J, Zhao X, Jiang X, He L, Wu X, Wang J, Chen Q, Li Y, Zhang M. Tubastatin A Improves Post-Resuscitation Myocardial Dysfunction by Inhibiting NLRP3-Mediated Pyroptosis Through Enhancing Transcription Factor EB Signaling. J Am Heart Assoc 2022;:e024205. [PMID: 35322683 DOI: 10.1161/JAHA.121.024205] [Reference Citation Analysis]
7 Vogelmann A, Jung M, Hansen FK, Schiedel M. Comparison of Cellular Target Engagement Methods for the Tubulin Deacetylases Sirt2 and HDAC6: NanoBRET, CETSA, Tubulin Acetylation, and PROTACs. ACS Pharmacol Transl Sci . [DOI: 10.1021/acsptsci.2c00004] [Reference Citation Analysis]
8 Zhou M, Yuan M, Zhang M, Lei C, Aras O, Zhang X, An F. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. Eur J Med Chem 2021;226:113825. [PMID: 34562854 DOI: 10.1016/j.ejmech.2021.113825] [Reference Citation Analysis]
9 Li S, Zhao C, Zhang G, Xu Q, Liu Q, Zhao W, James Chou C, Zhang Y. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity. Bioorg Chem 2021;116:105278. [PMID: 34474303 DOI: 10.1016/j.bioorg.2021.105278] [Reference Citation Analysis]
10 Zhang XH, Kang HQ, Tao YY, Li YH, Zhao JR, Ya-Gao, Ma LY, Liu HM. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity. Eur J Med Chem 2021;218:113392. [PMID: 33831778 DOI: 10.1016/j.ejmech.2021.113392] [Reference Citation Analysis]
11 Kurohara T, Tanaka K, Takahashi D, Ueda S, Yamashita Y, Takada Y, Takeshima H, Yu S, Itoh Y, Hase K, Suzuki T. Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group. Chembiochem 2021. [PMID: 34224197 DOI: 10.1002/cbic.202100255] [Reference Citation Analysis]
12 Samuelov L, Bochner R, Magal L, Malovitski K, Sagiv N, Nousbeck J, Keren A, Fuchs-Telem D, Sarig O, Gilhar A, Sprecher E. Vorinostat, a histone deacetylase inhibitor, as a potential novel treatment for psoriasis. Exp Dermatol 2021. [PMID: 34787924 DOI: 10.1111/exd.14502] [Reference Citation Analysis]
13 Liang T, Xue J, Yao Z, Ye Y, Yang X, Hou X, Fang H. Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors. Eur J Med Chem 2021;221:113526. [PMID: 33992929 DOI: 10.1016/j.ejmech.2021.113526] [Reference Citation Analysis]
14 Barone S, Cassese E, Alfano AI, Brindisi M, Summa V. Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology. J Med Chem 2022. [PMID: 35148101 DOI: 10.1021/acs.jmedchem.1c02067] [Reference Citation Analysis]
15 Zhang M, Wei W, Peng C, Ma X, He X, Zhang H, Zhou M. Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy. Bioorg Med Chem Lett 2021;49:128286. [PMID: 34314844 DOI: 10.1016/j.bmcl.2021.128286] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Zhang T, Zhao X, Sun X, Tian W, Wang C, Wang M, Zhang Y, Chen X, Zheng C. Design, synthesis, and biological evaluation of novel histone deacetylase 6 selective inhibitors. Journal of Saudi Chemical Society 2022. [DOI: 10.1016/j.jscs.2022.101450] [Reference Citation Analysis]
17 Li Y, Sang S, Ren W, Pei Y, Bian Y, Chen Y, Sun H. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020). Eur J Med Chem 2021;226:113874. [PMID: 34619465 DOI: 10.1016/j.ejmech.2021.113874] [Reference Citation Analysis]
18 Wang XX, Xie F, Jia CC, Yan N, Zeng YL, Wu JD, Liu ZP. Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease. Eur J Med Chem 2021;225:113821. [PMID: 34517222 DOI: 10.1016/j.ejmech.2021.113821] [Reference Citation Analysis]
19 Brusa I, Sondo E, Falchi F, Pedemonte N, Roberti M, Cavalli A. Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives. J Med Chem 2022. [PMID: 35377645 DOI: 10.1021/acs.jmedchem.1c01897] [Reference Citation Analysis]
20 Neganova M, Aleksandrova Y, Suslov E, Mozhaitsev E, Munkuev A, Tsypyshev D, Chicheva M, Rogachev A, Sukocheva O, Volcho K, Klochkov S. Novel Multitarget Hydroxamic Acids with a Natural Origin CAP Group against Alzheimer's Disease: Synthesis, Docking and Biological Evaluation. Pharmaceutics 2021;13:1893. [PMID: 34834312 DOI: 10.3390/pharmaceutics13111893] [Reference Citation Analysis]
21 Ojha R, Chen IC, Hsieh CM, Nepali K, Lai RW, Hsu KC, Lin TE, Pan SL, Chen MC, Liou JP. Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent. J Med Chem 2021;64:17824-45. [PMID: 34908406 DOI: 10.1021/acs.jmedchem.1c00966] [Reference Citation Analysis]
22 Sabnis RW. Novel Histone Deacetylase Inhibitors for Treating HIV Infection. ACS Med Chem Lett 2021;12:1196-7. [PMID: 34413939 DOI: 10.1021/acsmedchemlett.1c00336] [Reference Citation Analysis]